Pharmacological Neuroprotection in Cardiac Surgery: Effectiveness of Pharmacologic-Preconditioning with Erythromycin.

Pharmacological Neuroprotection in Cardiac Surgery: Effectiveness of Pharmacologic-Preconditioning with Erythromycin.

Click the title to purchase the article.

Abstract:

"Regardless of the degree of advances in neuroprotective strategies, and despite the technological progress in neuromonitoring, brain injury still remains the “Achilles' heel” in cardiac surgery. A large number of pharmacological and non-pharmacological therapeutic interventions have been investigated during the last two decades. Recently, both theoretical and experimental findings suggest benefits of pharmacological cerebral protection, although, there is no conclusive evidence of clinical superiority of specific agents that have been applied as neuroprotectants, in human randomized controlled trials. Pre-ischemic conditioning has also been used in an attempt to reduce the incidence of brain injury following cardiac surgery. In light of previous evidence showing that pharmacologic preconditioning with a single dose of erythromycin induces tolerance against transient global cerebral ischemia in rats, we examined whether erythromycin would reduce the number of apoptotic neurons in the neocortex in our acute porcine model of hypothermic circulatory arrest (HCA). Pre-ischemic conditioning with a single dose of the antibiotic erythromycin, applied 12 hours before HCA, significantly reduced neuronal injury in the neocortex of the porcine brain, suggesting that cerebral protection may be achieved with erythromycin pharmacological preconditioning in cardiac surgery on an experimental basis. Since erythromycin has been effectively used in clinical practice with few side effects, these findings suggest that it could be a promising candidate for potential clinical neuroprotective strategy."1


1. Pharmacological Neuroprotection in Cardiac Surgery: Effectiveness of Pharmacologic-Preconditioning with Erythromycin.
Koutsogiannidis CC, Johnson EO.
Curr Vasc Pharmacol. 2017 Oct 10. [Epub ahead of print]

 

Recent Stories
2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.

Predictive Factors of Long-Term Stay in the ICU after Cardiac Surgery: Logistic CASUS Score, Serum Bilirubin Dosage and Extracorporeal Circulation Time.

Percutaneous left atrial unloading to prevent pulmonary oedema and to facilitate ventricular recovery under extracorporeal membrane oxygenation therapy. FREE

AmSECT Membership Eligibility

An Active Member shall be any perfusionist active in the practice of extracorporeal circulation technology. There are also opportunities to become a Transitional Active Member for those less than a year removed from graduation from an approved accredited training program. Other options include; an Associate Membership, International Membership, Perioperative Blood Management Clinician Membership, and Student Membership.

Click Here to Learn More

Looking for Employment Opportunities?

AmSECT members may post an available position for a perfusion specialty at your institution or firm.

Non-members may also post positions free of charge, to be reviewed by National Headquarters prior to posting.

Members - Click to Post a Position
Non-Members - Click to Post a Position

Contact AmSECT


AmSECT National Headquarters
330 N Wabash Ave, Suite 2000
Chicago, IL 60611

  Phone: (312) 321-5156
  Fax: (312) 673-6656
  Email: amsect@amsect.org

AmSECT © 2018 | View Privacy Policy | Site Map